

■ Clonidine

Clonidine decreases the release of norepinephrine by acting on presynaptic noradrenergic receptors, and is commonly used in clinical practice to treat hypertension. It has been used since the 1980s to treat the autonomic symptoms caused by noradrenergic hyperactivity associated with withdrawal [7,8]. However, the overall efficacy of clonidine is only moderate in reducing withdrawal symptoms, and is less effective than opioid agonists at relieving anxiety, sleeplessness, muscle aches and craving associated with OW. Clonidine is also associated with severe side-effects such as hypotension and sedation that limit its use to medically supervised environments [9].

■ Methadone

Drugs that bind to opioid receptors are also used to treat OW during the detoxification process. Methadone is often used as a substitute for heroin, and strongly reduces withdrawal symptoms [10]. However, opioid agonists like methadone, which is very potent and long-acting, are difficult to use by nonexperts, are associated with potentially severe side effects and abuse, and are subject to US Drug Enforcement Administration schedule II restrictions. Methadone is difficult to titrate rapidly and safely for the relief of withdrawal symptoms, and it is difficult to use for rapid detoxification outside of a medically monitored environment.

■ Buprenorphine

Buprenorphine is a newer drug used for opioid detoxification. It is a partial μ -opioid agonist and κ -receptor antagonist that has been found to be more effective than clonidine and about as effective as methadone when used for opioid detoxification [11]. However, physicians must meet certain qualifications and be granted a special waiver to prescribe buprenorphine for treatment of opioid dependency. The institution of buprenorphine therapy can also exacerbate withdrawal symptoms, especially if large doses of longer acting opioids have been used by the patient. Compliance with and adherence to outpatient therapy has also been identified as an area in which improvement is needed [12].

Better opioid withdrawal treatments are needed

Current medications used to reduce symptoms of OW all possess specific drawbacks that make existing treatments inadequate. Potential for drug abuse, dangerous side effects and barriers

to treatment have led to the search for alternative treatment approaches. The ideal agent to reduce symptoms of OW should involve a nonopioid, nonaddicting medication to minimize the potential for abuse. It should prevent the development of physical dependence and/or treat the symptoms of acute withdrawal with a wide therapeutic window and low side-effect profile, and should be available in a wide variety of formulations (e.g., intravenous, oral). This type of medication would improve access to effective treatment, particularly in non-monitored outpatient settings, and could radically improve treatment of opioid dependence. A treatment that could prevent the development of OW may also ameliorate other problems associated with physical dependence, such as analgesic tolerance and opioid-induced hyperalgesia. We believe drugs that target the 5HT₃ receptor may fulfill these criteria.

A new approach: 5HT₃ receptor antagonist drugs

Recent evidence from our laboratories, employing pharmacogenetic haplotype-based computational mapping, have linked the 5HT₃ receptor to physical dependence and OW [13]. These agents offer several advantages, including a very benign side-effect profile, several available forms of administration and little potential for abuse.

■ Physiology of the 5HT₃ receptor

The 5HT₃ receptor is a ligand-gated cation channel found on neurons in the central and peripheral nervous systems, other cell types such as mononuclear cells and intestinal enterochromaffin cells. These receptors modulate neurotransmitter and neuropeptide release of dopamine, GABA, substance P, cholecystokinin, acetylcholine and even serotonin itself. In the CNS, 5HT₃ receptors are found primarily on GABAergic neurons in the area postrema, nucleus tractus solitarius, nucleus dorsalis nervi vagi, nucleus caudatus, nucleus accumbens, amygdala, hippocampus, entorhinal cortex, frontal cortex, cingulate cortex and dorsal horn ganglia [12]. These locations suggest involvement with the vomiting reflex, pain processing and control of anxiety [14].

Despite the diverse location and action of 5HT₃ receptors in the CNS and periphery, blockade of 5HT₃ receptors in animal experiments does not change normal behavior. The only changes noted in healthy human volunteers were occasional constipation and clinically insignificant changes in

cardiac conduction patterns without evidence of CNS effects. There are several 5HT₃ receptor antagonists already on the market and approved by the US FDA. The 5HT₃ receptor antagonist ondansetron has been available in the US market since FDA approval was granted in 1991, and is a well-tolerated drug with few side effects.

■ Evidence for 5HT₃ modulation of opioid withdrawal

Several lines of evidence point to the role of 5HT₃ receptor antagonists in reducing OW. In addition to pharmacogenetic evidence, our work in animal models has shown that the 5HT₃ receptor antagonist ondansetron treats and prevents OW in mice in a dose-dependent manner [13]. Morphine-induced physical dependence is also associated with decreased 5HT₃ protein expression and downregulation of *Htr3a* gene expression in brainstem nuclei associated with opioid dependence in mice [13]. Additional data from our laboratories in a series of translational studies shows that the 5HT₃ receptor antagonist ondansetron can significantly decrease objective measures of OW by up to 76% in humans [13]. We have since conducted an additional study confirming the efficacy of another 5HT₃ antagonist, palanosetron, in decreasing objective measures of OW, implicating a drug class effect (unpublished data).

Although data are far less clear and compelling, 5HT₃ receptor antagonists have also been considered for the treatment of addiction [15,16]. Some of the laboratory evidence supporting these considerations includes observations that 5HT₃ receptors modulate the mesolimbic dopamine reward system, implicated in reinforcing effects of drugs of abuse [17]. Other animal studies implicate 5HT₃ receptors in addiction and withdrawal as well. *Htr3a*-deficient mice display diminished sensitization to cocaine [18]. Ondansetron reduces the conditioned place preference induced by morphine in rodents, which is a measure of the use-reinforcing properties of addictive drugs [19].

Significance & future perspective

Ondansetron and other 5HT₃ antagonists offer exciting new treatment options for OW. Strong

preclinical evidence in animals and early translational studies in humans from our group support our hypothesis that 5HT₃ receptor antagonists are effective in treating many OW signs and symptoms [13]. Other studies from the medical literature provide evidence that supports the biological plausibility of our hypothesis. The implications of the finding that 5HT₃ receptor antagonists reduce OW are substantial. It will have a dramatic impact on our ability to treat opioid abuse by offering an effective, easily delivered, low-cost method to detoxify patients from opioid therapy with low side effects and potential for abuse.

“Ondansetron and other 5HT₃ antagonists offer exciting new treatment options for opioid withdrawal.”

However, despite these promises, much more work must be done. Our findings, while novel, need to be confirmed in larger high-quality translational studies and clinical trials. The precise molecular mechanisms and pathways by which 5HT₃ receptor antagonists modulate OW require further elucidation; molecular and MRI imaging may assist this work. The ability for 5HT₃ receptor antagonists to prevent multiple domains of physical dependence, including opioid tolerance and hyperalgesia, if co-administered with opioid therapy, is an intriguing theory that is derived from our findings. Finally, combination of 5HT₃ receptor antagonists with other agents to treat withdrawal may lead to even more efficacious treatments for this troublesome medical problem.

Financial & competing interests disclosure

Dr Chu's work is supported by a Career Development Award from the National Institute of General Medical Sciences of the National Institutes of Health, grant number 5K23GM071400. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Bibliography

- 1 Kane H: *The Hypodermic Injection of Morphia: Its History, Advantages and Dangers (Based on the Experience of 360 Physicians)*. 1st Edition. Chas L Birmingham & Co., NY, USA, 354 (1880).
- 2 Cami J, Farre M: Drug addiction. *N. Engl. J. Med.* 349(10), 975–986 (2003).
- 3 Franken IH, Hendriks VM: Predicting outcome of inpatient detoxification of substance abusers. *Psychiatr. Serv.* 50(6), 813–817 (1999).
- 4 Jage J: Opioid tolerance and dependence – do they matter? *Eur. J. Pain* 9(2), 157–162 (2005).
- 5 Caillé S, Espejo EF, Reneric JP, Cador M, Koob GF, Stinus L: Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal. *J. Pharmacol. Exp. Ther.* 290(2), 881–892 (1999).
- 6 Nestler EJ: Molecular basis of long-term plasticity underlying addiction. *Nat. Rev. Neurosci.* 2, 119–128 (2001).
- 7 Gold MS, Redmond DE, Jr, Kleber HD: Clonidine blocks acute opiate-withdrawal symptoms. *Lancet* 2, 599–602 (1978).
- 8 Gold MS, Redmond DE, Jr, Kleber HD: Clonidine in opiate withdrawal. *Lancet* 1, 929–930 (1978).
- 9 Washton AM, Resnick RB: Clonidine in opiate withdrawal: review and appraisal of clinical findings. *Pharmacotherapy* 1(2), 140–146 (1981).
- 10 Amato L, Davoli M, Minozzi S, Ali R, Ferri M: Methadone at tapered doses for the management of opioid withdrawal. *Cochrane Database Syst. Rev.* 3, CD003409 (2005).
- 11 Gowing L, Ali R, White J: Buprenorphine for the management of opioid withdrawal. *Cochrane Database Syst. Rev.* 2, CD002025 (2006).
- 12 Boothby LA, Doering PL: Buprenorphine for the treatment of opioid dependence. *Am. J. Health Syst. Pharm.* 64(3), 266–272 (2007).
- 13 Chu LF, Liang DY, Li X *et al.*: From mouse to man: the 5-HT₃ receptor modulates physical dependence on opioid narcotics. *Pharmacogenet. Genomics* 19(3), 193–205 (2009).
- 14 Färber L, Haus U, Späth M, Drechsler S: Physiology and pathophysiology of the 5-HT₃ receptor. *Scand. J. Rheumatol Suppl.* 119, 2–8 (2004).
- 15 Gyermek L: 5-HT₃ receptors: pharmacologic and therapeutic aspects. *J. Clin. Pharmacol.* 35, 845–855 (1995).
- 16 Tricklebank MD: Interactions between dopamine and 5-HT₃ receptors suggest new treatments for psychosis and drug addiction. *Trends Pharmacol. Sci.* 10, 127–129 (1989).
- 17 Kauer JA, Malenka RC: Synaptic plasticity and addiction. *Nat. Rev. Neurosci.* (11), 844–858 (2007).
- 18 Hodge CW, Bratt AM, Kelley SP: Deletion of the 5-HT_{3A}-receptor subunit blunts the induction of cocaine sensitization. *Genes Brain Behav.* 7(1), 96–102 (2008).
- 19 Higgins GA, Nguyen P, Joharchi N, Sellers EM: Effects of 5-HT₃ receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. *Psychopharmacology (Berl.)* 105(3), 322–328 (1991).